DE69615808T2 - Camphothecinderivate - Google Patents

Camphothecinderivate

Info

Publication number
DE69615808T2
DE69615808T2 DE69615808T DE69615808T DE69615808T2 DE 69615808 T2 DE69615808 T2 DE 69615808T2 DE 69615808 T DE69615808 T DE 69615808T DE 69615808 T DE69615808 T DE 69615808T DE 69615808 T2 DE69615808 T2 DE 69615808T2
Authority
DE
Germany
Prior art keywords
camphothecinderivate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69615808T
Other languages
English (en)
Other versions
DE69615808D1 (de
Inventor
Kenji Tsujihara
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP34357595 priority Critical
Priority to JP20010596 priority
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of DE69615808D1 publication Critical patent/DE69615808D1/de
Publication of DE69615808T2 publication Critical patent/DE69615808T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0018Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
DE69615808T 1995-12-28 1996-12-23 Camphothecinderivate Expired - Lifetime DE69615808T2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP34357595 1995-12-28
JP20010596 1996-07-30

Publications (2)

Publication Number Publication Date
DE69615808D1 DE69615808D1 (de) 2001-11-15
DE69615808T2 true DE69615808T2 (de) 2002-05-02

Family

ID=26511972

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615808T Expired - Lifetime DE69615808T2 (de) 1995-12-28 1996-12-23 Camphothecinderivate

Country Status (15)

Country Link
US (3) US5892043A (de)
EP (1) EP0781781B1 (de)
KR (1) KR100352545B1 (de)
CN (2) CN1142935C (de)
AT (1) AT206720T (de)
CA (1) CA2192725C (de)
DE (1) DE69615808T2 (de)
DK (1) DK0781781T3 (de)
ES (1) ES2164218T3 (de)
GR (1) GR3037076T3 (de)
ID (1) ID25979A (de)
MX (1) MX9700222A (de)
PT (1) PT781781E (de)
SG (2) SG49994A1 (de)
TW (1) TW473478B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888988A (en) * 1995-05-08 1999-03-30 Chitogenics, Inc. Covalently linked N,O-carboxymethylchitosan and uses thereof
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DK0934329T3 (da) * 1996-09-30 2002-04-08 Bayer Ag Glycokonjugater af modificerede camptothecinderivater (20-O-binding)
DE19640207A1 (de) * 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU3733399A (en) * 1998-05-22 1999-12-13 Daiichi Pharmaceutical Co., Ltd. Drug composites
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
AT242638T (de) * 1998-11-25 2003-06-15 Nutri Pharma As Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
EP2289549A3 (de) 1999-10-01 2011-06-15 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
PL354623A1 (xx) * 1999-10-12 2004-02-09 Cell Therapeutics, Inc. Method for producing polyglutamate conjugates with a therapeutic agent
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
CN100393724C (zh) * 2002-07-12 2008-06-11 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
WO2006027567A2 (en) * 2004-09-07 2006-03-16 Biocompatibles Uk Limited Drug delivery from embolic agents
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
EP3342785B1 (de) 2012-10-11 2019-12-25 Daiichi Sankyo Company, Limited Linkers für kojugaten enthaltend antikörper und medicamenten
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
KR102237803B1 (ko) 2013-12-25 2021-04-09 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
EP3466976A1 (de) 2014-01-31 2019-04-10 Daiichi Sankyo Company, Limited Anti-her2-antikörper-wirkstoff-konjugat
SG11201608309PA (en) 2014-04-10 2016-11-29 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
RU2019123616A (ru) 2017-01-17 2021-02-19 Дайити Санкио Компани, Лимитед Антитело против gpr20 и конъюгаты антитело против gpr20-лекарственное средство

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682874D1 (de) 1985-10-21 1992-01-23 Daiichi Seiyaku Co Pyranoindolizinderivate und verfahren zu ihrer herstellung.
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
JP2540357B2 (ja) 1987-06-24 1996-10-02 株式会社ヤクルト本社 六環性化合物
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0540099B1 (de) 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Wasserlösliche Camptothecinderivate
JPH06228141A (ja) 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
JP3359955B2 (ja) 1992-07-16 2002-12-24 株式会社ヤクルト本社 抗腫瘍剤
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Inst Ltd Polysaccharidderivat und wirkstoffträger
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives

Also Published As

Publication number Publication date
DE69615808D1 (de) 2001-11-15
EP0781781A2 (de) 1997-07-02
CA2192725A1 (en) 1997-06-29
US5892043A (en) 1999-04-06
CN1073113C (zh) 2001-10-17
KR100352545B1 (ko) 2003-01-24
CN1300733A (zh) 2001-06-27
ES2164218T3 (es) 2002-02-16
GR3037076T3 (en) 2002-01-31
PT781781E (pt) 2002-03-28
TW473478B (en) 2002-01-21
AT206720T (de) 2001-10-15
ID25979A (id) 1997-06-26
KR970042553A (ko) 1997-07-24
US6512118B1 (en) 2003-01-28
CN1158334A (zh) 1997-09-03
CN1142935C (zh) 2004-03-24
MX9700222A (es) 1998-04-30
EP0781781A3 (de) 1998-04-01
SG76585A1 (en) 2000-11-21
CA2192725C (en) 2004-04-20
EP0781781B1 (de) 2001-10-10
DK781781T3 (de)
SG49994A1 (en) 1998-06-15
US6617456B1 (en) 2003-09-09
DK0781781T3 (da) 2001-11-26

Similar Documents

Publication Publication Date Title
DE69625084D1 (de) Kostengebiete
DE69529921T2 (de) Bewegungsunterstütztes weiterreichungsverfahren
DE69620534T2 (de) Schuh-Bindungseinheit
NO982625L (no) R°rkopling
DK0822982T3 (da) Cyclomaltodextringlucanotransferasevarianter
DE69618179T2 (de) Arylsulfonylaminohydroxamsäurederivate
DE69628352D1 (de) Zwischenwirbelfusionierungseinrichtung
DE69630817T8 (de) Wirbelsäulenhalterunsvorrichtung
DE69620884D1 (de) Kodemultiplexvielfachzugriffsnachrichtenübertragungssystem
DE69638011D1 (de) Ngriff
DE69633756D1 (de) Spondylodeseimplantate
DE69617955T2 (de) Implantat-verbindemechanismus
DE69636130D1 (de) Permeatsammelsystem
DE69633284D1 (de) Nähfadenzange
DE69630711D1 (de) Bausystem
DE69629037D1 (de) Oberflächenplasmanenresonanzmassenspektrometrie
DE69618032D1 (de) Estersynthese
DE69638219D1 (de) Teilchentrennverfahren
DE69621290D1 (de) Hydroxycarbylsiloxy-Aluminoxanzusammensetzungen
DE69615906T2 (de) Kontakhalterungssystem
DE69635184T2 (de) Vielfachkapillarfluoreszenzsensoranordnung
DE69604502D1 (de) Anzeigetafeln
DE69628358D1 (de) Plasmaätzmethode
DE69636741D1 (de) Bleichkatalysatorteilchen
DE69629333D1 (de) Adduktabschirmungstest

Legal Events

Date Code Title Description
8364 No opposition during term of opposition